Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Circulating tumor DNA-based minimal residual disease assessment predicts progression-free survival in diffuse large B-cell lymphoma: A systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZMZuha MajidKing Edward Medical University

Discussion

Loading...

Member takes

Implication

Systematic review demonstrates ctDNA MRD predicts inferior progression-free survival in DLBCL, suggesting imaging limitations.

Key Points

  • To assess the prognostic impact of ctDNA minimal residual disease status on progression-free survival in DLBCL.
  • Systematic review and meta-analysis conducted on studies from PubMed, Embase, and Cochrane databases.
  • Included studies provided PFS outcomes based on EOT ctDNA MRD status in patients with DLBCL.
  • Risk ratios comparing MRD-positive to MRD-negative groups were calculated; pooled results analyzed using random-effects model.
  • Eight studies with 490 patients included in the analysis.
  • MRD-positive patients exhibited significantly inferior progression-free survival compared to MRD-negative patients.
  • Pooled risk ratio of 0.27 indicated a 73% higher risk of disease progression in MRD-positive patients.

Cite This Study

Zuha Majid (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0d9https://doi.org/10.1182/blood-2025-3548
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integration of longitudinal ctdna MRD and PET/CT enhances prognostic stratification in newly diagnosed diffuse large B-cell lymphoma: A prospective multicenter study2025
  2. 2Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma2025 · 35 citations
  3. 3Prognostic value of minimal residual disease detection by circulating tumor DNA in Hodgkin lymphoma.2025
  4. 4Circulating tumour DNA as a predictor of survival of patients with diffuse large B‐cell lymphoma in a daily practice2025 · 1 citations
  5. 5Minimal residual disease as a prognostic marker in chronic lymphocytic leukemia: A meta-analysis across chemoimmunotherapy and targeted therapies2025